Related Experiment Video
Updated: Jul 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Granulomatous hepatitis after intravesical BCG treatment for bladder cancer
Osman Ersoy1, Rasit Aran, Musa Aydinli
1Department of Gastroenterology, Hacettepe University Faculty of Medicine, Ankara, Turkey. roersoy@tnn.net
Abstract:
Intravesical bacillus Calmette-Guerin (BCG) is used in patients with urinary bladder carcinoma. Although it is generally well tolerated, granulomatous hepatitis is a rare but serious complication. We report a 42-year-old man and a 56-year-old man who developed granulomatous hepatitis following intravesical BCG. One of them was treated successfully with antitubercular therapy; the other died because of BCG sepsis and multi-organ failure.